ALLO

Allogene Therapeutics' stock has experienced significant positive movement, with a 110.58% increase in the past six months. Positive interim data from the ALPHA3 trial led to a stock surge, while a public offering caused short-term adjustments. Trial expansion and pre-clinical data publication also influenced the stock. Analyst ratings have been mixed, with some firms increasing price targets and others maintaining "sell" or "hold" ratings.